US0463531089
© BusinessWire
06.01.2025
AZN
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Continues Its Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
News Preview
The Law Offices of Frank R. Cruz continues its investigation on behalf of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On November 5, 2024, news outlets re...
Themefolio
Profiler
Peergroup
© BusinessWire
05.01.2025
AZN
LISTED
NASDAQ
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca” or “the Company”) (NASDAQ: AZN) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged v...
Themefolio
Profiler
Peergroup
© BusinessWire
04.01.2025
AZN
LISTED
NASDAQ
AZN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”), have until February 21, 2025 to seek appointment as lead plaintiff of the AstraZeneca class action lawsui...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
03.01.2025
AZN
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Encourages AstraZeneca PLC (AZN) Investors to Inquire About Securities Fraud Class Action
News Preview
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
02.01.2025
AZN
LISTED
NASDAQ
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AstraZeneca PLC (AZN) Investors
News Preview
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024, inclusive (the “Class Period”). AstraZeneca investors have until February 21, 2025 to file a lead plainti...
Themefolio
Profiler
Peergroup
© BusinessWire
31.12.2024
AZN
LISTED
NASDAQ
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC (“AstraZeneca” or “the Company”) (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Inv...
Themefolio
Profiler
Peergroup
© BusinessWire
27.12.2024
AZN
LISTED
NASDAQ
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca” or “the Company”) (NASDAQ: AZN) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged v...
Themefolio
Profiler
Peergroup
© BusinessWire
26.12.2024
AZN
LISTED
NASDAQ
ASTRAZENECA SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against AstraZeneca PLC - AZN
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 21, 2025 to file lead plaintiff applications in a securities class action lawsuit against AstraZeneca PLC (the “Company”) (NasdaqGS: AZN), if they purchased the Company’s securities between...
Themefolio
Profiler
Peergroup
© BusinessWire
23.12.2024
AZN
LISTED
NASDAQ
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of AstraZeneca PLC Investors – AZN
News Preview
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for AstraZeneca PLC investors under the federal secu...
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2024
AZN
LISTED
NASDAQ
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Koselugo (selumetinib) for the treatment of paediatric patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform
News Preview
The agreement is a critical step in ensuring paediatric patients living with NF1 PN have public access to Koselugo, the only approved therapy in Canada for this rare disease
MISSISSAUGA, ON, Dec. 18, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, has entered into a Letter of Intent (LOI) with the pan-Canadian Pharmace...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
AZN
LISTED
NASDAQ
Rosen Law Firm Encourages AstraZeneca PLC Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – AZN
News Preview
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AstraZeneca PLC (NASDAQ: AZN) resulting from allegations that AstraZeneca may have issued materially misleading business information to the investing public.
So What: If you purchased AstraZeneca securiti...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
AZN
LISTED
NASDAQ
LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
News Preview
Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA® (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS) and distant disease-free survival (DDFS) at six years for patients...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
09.12.2024
AZN
LISTED
NASDAQ
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
News Preview
Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR-tyrosine kinase inhibitor (TKI) a...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2024
AZN
LISTED
NASDAQ
Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
News Preview
Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lympho...
Themefolio
Profiler
Peergroup
© BusinessWire
06.12.2024
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) granted Priority Review in the US for patients with muscle-invasive bladder cancer
News Preview
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC).
The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer sign...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2024
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
News Preview
AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.
The approval was granted by the Food and Drug Administration (FDA) after securing Priority...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
AZN
LISTED
NASDAQ
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
News Preview
Law Offices of Howard G. Smith announces an investigation on behalf of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) investors concerning the Company’s possible violations of federal securities laws.
On November 5, 2024, news outlets reported that a fraud investigation linked to AstraZeneca had expanded to several Chinese govern...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
AZN
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) investors concerning the Company’s possible violations of the federal securities laws.
If you suffered a loss on your AstraZene...
Themefolio
Profiler
Peergroup
© BusinessWire
04.12.2024
AZN
LISTED
NASDAQ
The Law Offices of Frank R. Cruz Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors
News Preview
The Law Offices of Frank R. Cruz announces an investigation of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) on behalf of investors concerning the Company’s possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On November 5, 2024, news outlets reported that a...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
AZN
LISTED
NASDAQ
TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
News Preview
Positive high-level results from the CAPItello-281 Phase III trial showed that AstraZeneca’s TRUQAP® (capivasertib) in combination with abiraterone and androgen deprivation therapy (ADT) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival (rPFS) versus abi...
Themefolio
Profiler
Peergroup
© BusinessWire
20.11.2024
AZN
LISTED
NASDAQ
AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
News Preview
AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This brings the total contributions from the program to more than $15 million to date.
Now...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2024
AZN
LISTED
NASDAQ
TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
News Preview
Positive high-level results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]) showed that AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to...
Themefolio
Profiler
Peergroup
© BusinessWire
07.11.2024
AZN
LISTED
NASDAQ
AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
News Preview
AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in hematology at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition December 7-10, 2024.
A total of 57 abstracts will feature 13 approved and potential new medicines from across AstraZeneca’s portfolio...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2024
AZN
LISTED
NASDAQ
AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
News Preview
Positive high-level results from the BATURA Phase IIIb trial showed AstraZeneca’s AIRSUPRA ® (albuterol/budesonide) met the primary endpoint, demonstrating a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed al...
Themefolio
Profiler
Peergroup
© BusinessWire
03.10.2024
AZN
LISTED
NASDAQ
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
News Preview
AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
News Preview
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2 ultralow (IHC 0 with membrane staining) breast cancer...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2024
AZN
LISTED
NASDAQ
TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
News Preview
AstraZeneca’s TAGRISSO® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy (CRT). TAGRISSO i...
Themefolio
Profiler
Peergroup
© BusinessWire
23.09.2024
AZN
LISTED
NASDAQ
Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
News Preview
High-level results from the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd) compared to investigator’s choice of chemotherapy, which previously met the dual primary endpoint of progression-free survival (PFS), did not achieve statistical significance in the final overall survival (OS) analysis in patients with inoperable or m...
Themefolio
Profiler
Peergroup
© BusinessWire
20.09.2024
AZN
LISTED
NASDAQ
FLUMIST approved for self-administration in the US
News Preview
FLUMIST® has been approved in the US as the only self-administered influenza vaccine. FLUMIST, a needle-free nasal spray, was approved to be self-administered by adults up to 49 years of age or administered by a parent/caregiver to individuals 2-17 years of age.1
The approval by the US Food and Drug Administration (FDA) was based on a comprehensi...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2024
AZN
LISTED
NASDAQ
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
News Preview
AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal.2,3
The approval by the US Food and Drug Administration (FDA)...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2024
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
News Preview
Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at five years for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for...
Themefolio
Profiler
Peergroup
© BusinessWire
15.09.2024
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
News Preview
Positive results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for...
Themefolio
Profiler
Peergroup
© BusinessWire
13.09.2024
AZN
LISTED
NASDAQ
ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
News Preview
Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial clinical activity in a large cohort of patients with HER2-positive metastatic breast cancer who have brain metastases and received no more than two prior lines of therapy in the metastatic s...
Themefolio
Profiler
Peergroup
© BusinessWire
09.09.2024
AZN
LISTED
NASDAQ
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
News Preview
Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy, in adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) treated wi...
Themefolio
Profiler
Peergroup
© BusinessWire
08.09.2024
AZN
LISTED
NASDAQ
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
News Preview
Results from an exploratory analysis of the TROPION-Lung01 Phase III trial showed TROP2 as measured by AstraZeneca’s proprietary computational pathology platform, quantitative continuous scoring (QCS), was predictive of clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who were treated with datopotamab de...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
AZN
LISTED
NASDAQ
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
News Preview
AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the IASLC 2024 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, September 7 to 10, 2024 and the European Society for Medical Oncology (ESMO) Congress...
Themefolio
Profiler
Peergroup
© BusinessWire
16.08.2024
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
News Preview
AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. In this regimen, patients a...
Themefolio
Profiler
Peergroup
© BusinessWire
15.08.2024
AZN
LISTED
NASDAQ
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
News Preview
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab), based on the results from the positive ADRIATIC Phase III trial in patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based concurrent chemoradiotherapy (cCRT), has been accepted and granted Prior...
Themefolio
Profiler
Peergroup
© PR Newswire
04.06.2024
AZN
LISTED
NASDAQ
AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024
News Preview
CAR031 study at 9.03-mo median follow up achieves disease control rate (DCR) of 91.3% and objective response rate (ORR) of 56.5% for patients across all dose levels (DLs) and ORR of 75.0% at DL4
ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focu...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
